-
Engineering any genome, at any site, in any way
-
Focused on the advancement of new applications for CRISPR-based technologies
-
Exploring the vast potential of CRISPR-Cas technology across therapeutics, agricultural biotech, biological research and industrial biotech
News
Caribou Biosciences Co-Founder Dr. Jennifer Doudna Awarded Nobel Prize in Chemistry
October 7, 2020BERKELEY, CA – October 7, 2020 – Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, today announced that co-founder Jennifer Doudna, Ph.D., has been awarded the 2020 Nobel Prize in Chemistry....
Caribou Biosciences Announces FDA Clearance of its IND for CB-010, an Off-the-shelf Allogeneic Anti-CD19 CAR-T Cell Therapy
September 8, 2020First allogeneic CAR-T cell therapy with PD-1 deleted by CRISPR genome editing cleared for Phase 1 clinical trials
Upon initiation of the ANTLER Phase 1 clinical trial, CB-010 will be Caribou’s first clinical-stage product candidate...
Our Approach
Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing. Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole.
Our singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality.